A breakthrough in vision restoration technology has moved closer to commercial use after Science Corp., a U.S.-based neurotechnology startup, received European Union (CE Mark) approval for its Prima bionic eye system. The approval allows the company to begin offering the implant commercially in Europe, making it one of the first vision-restoring devices of its kind to reach the market.
Designed for patients with geographic atrophy, an advanced form of age-related macular degeneration (AMD), the Prima system combines a tiny retinal implant with specialized smart glasses to help restore functional central vision. Unlike traditional brain-computer interface (BCI) devices that target movement or communication, Prima focuses on restoring sight by stimulating surviving retinal cells rather than directly interfacing with the brain.
How the Prima Vision Restoration System Works
The Prima system consists of two key components:
- A wireless retinal implant surgically placed beneath the retina.
- A pair of smart glasses equipped with a camera and near-infrared projector.
The glasses capture visual information and transmit it wirelessly to the implant, which converts light into electrical signals that stimulate the retina. These signals are then processed through the natural visual pathway to the brain, allowing patients to perceive images.
Prima Bionic Eye at a Glance
| Feature | Details |
|---|---|
| Developer | Science Corp. |
| Regulatory Milestone | CE Mark (European Union) |
| Target Condition | Geographic atrophy due to age-related macular degeneration |
| Implant Location | Beneath the retina |
| External Component | Smart glasses with camera and projector |
| Commercial Rollout | Expected to begin in Germany |
Clinical Trial Results Show Promising Outcomes
The CE approval follows clinical studies involving 38 patients with advanced macular degeneration.
According to the company:
- 84% of participants were able to read letters, numbers, or words using the system.
- The implant restored useful central vision without damaging patients’ remaining natural eyesight.
- The current version provides black-and-white vision within a relatively narrow central field of view.
Although image quality remains limited compared with natural vision, researchers describe the results as an important proof of concept for future generations of the technology.
Clinical Highlights
| Metric | Result |
|---|---|
| Patients Studied | 38 |
| Able to Read Letters/Numbers | 84% |
| Vision Type | Black and white |
| Field of View | Narrow central vision |
| Effect on Remaining Vision | No significant impairment reported |
A Different Approach From Neuralink’s Blindsight
Science Corp. was founded by Max Hodak, a co-founder of Neuralink, but Prima uses a different technological approach.
| Prima (Science Corp.) | Neuralink Blindsight |
|---|---|
| Stimulates surviving retinal cells | Designed to stimulate the visual cortex directly |
| Intended for retinal degeneration | Intended for blindness caused by optic nerve damage |
| Received EU CE Mark approval | Still under development and clinical evaluation |
| Commercial launch planned in Europe | Human testing remains limited |
While both technologies aim to restore vision, they target different causes of blindness and rely on different biological pathways.
Why the Approval Matters
Receiving the CE Mark allows Science Corp. to market the Prima system across eligible European markets, beginning with Germany.
The approval represents:
- One of the first commercially approved next-generation retinal implants.
- A significant milestone for vision restoration technologies.
- Progress in translating brain-computer and neuroprosthetic research into clinical treatments.
- A potential alternative for patients with limited treatment options for advanced macular degeneration.
Challenges Remain
Despite the milestone, the technology is still in its early stages.
Current limitations include:
- Black-and-white rather than full-color vision.
- A restricted central field of view.
- The need for surgical implantation.
- Suitability only for specific forms of retinal degeneration.
Researchers aim to improve image resolution, expand the field of view, and eventually deliver color vision in future versions.
Looking Ahead
The European approval of Science Corp.’s Prima system marks an important step toward making vision-restoring neurotechnology commercially available. By combining a retinal implant with smart glasses, the device offers new hope for people with advanced age-related macular degeneration who have few effective treatment options. While current visual restoration is limited to monochrome images within a narrow field of view, the technology demonstrates that meaningful functional vision can be restored through retinal stimulation.
Looking ahead, commercial deployment in Europe is expected to provide valuable real-world experience that could guide future improvements in resolution, color perception, and usability. As competition in neurotechnology intensifies—with companies such as Science Corp. and Neuralink pursuing different approaches to restoring vision—the field is moving closer to practical treatments that could transform the lives of patients with severe visual impairment.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
